ANGO logo

ANGO
Angiodynamic Inc

1,051
Mkt Cap
$462.77M
Volume
39,586.00
52W High
$13.99
52W Low
$8.36
PE Ratio
-14.74
ANGO Fundamentals
Price
$11.09
Prev Close
$11.20
Open
$11.13
50D MA
$10.84
Beta
1.09
Avg. Volume
369,931.51
EPS (Annual)
-$0.8321
P/B
2.69
Rev/Employee
$433,330.37
$364.75
Loading...
Loading...
News
all
press releases
AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of "Moderate Buy" by Analysts
AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the company, MarketBeat.com reports. One...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·4d ago
News Placeholder
AngioDynamics CEO Touts Debt-Free Turnaround, Auryon Share Gains, NanoKnife Launch at Needham Conf
AngioDynamics (NASDAQ:ANGO) CEO Jim Clemmer used a presentation at Needham & Company's 25th Annual Needham Healthcare Conference to outline the company's multi-year transformation, highlight growth...
MarketBeat·10d ago
News Placeholder
AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·14d ago
News Placeholder
AngioDynamics (NASDAQ:ANGO) Issues FY 2026 Earnings Guidance
AngioDynamics (NASDAQ:ANGO) updated its FY 2026 earnings guidance. The company provided EPS guidance of -0.300--0.230 for the period, compared to the consensus estimate of -0.280. The company also...
MarketBeat·15d ago
News Placeholder
AngioDynamics (ANGO) Upgraded to Buy: Here's Why
AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·16d ago
News Placeholder
HC Wainwright Increases Earnings Estimates for AngioDynamics
AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for AngioDynamics in a research report issued to clients and investors on Monday, April 6th. HC Wainwright analyst Y. Chen now forecasts that the medical instruments supplier wil...
MarketBeat·16d ago
News Placeholder
AngioDynamics (NASDAQ:ANGO) Raised to "Strong-Buy" at Freedom Capital
Freedom Capital raised shares of AngioDynamics to a "strong-buy" rating in a research report on Monday...
MarketBeat·16d ago
News Placeholder
Q3 EPS Estimates for AngioDynamics Lifted by HC Wainwright
AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Investment analysts at HC Wainwright lifted their Q3 2027 earnings estimates for shares of AngioDynamics in a note issued to investors on Monday...
MarketBeat·17d ago
News Placeholder
ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down
AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.
Zacks·18d ago
<
1
2
...
>

Latest ANGO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.